These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30106434)

  • 1. Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62.
    Alsamman K; El-Masry OS
    Oncol Rep; 2018 Oct; 40(4):2157-2162. PubMed ID: 30106434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.
    Nguyen EV; Huhtinen K; Goo YA; Kaipio K; Andersson N; Rantanen V; Hynninen J; Lahesmaa R; Carpen O; Goodlett DR
    Mol Cell Proteomics; 2017 Jul; 16(7):1377-1392. PubMed ID: 28455291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulation.
    Battista RA; Resnati M; Facchi C; Ruggieri E; Cremasco F; Paradiso F; Orfanelli U; Giordano L; Bussi M; Cenci S; Milan E
    PLoS One; 2018; 13(8):e0201621. PubMed ID: 30067838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
    Wang J; Garbutt C; Ma H; Gao P; Hornicek FJ; Kan Q; Shi H; Duan Z
    Gynecol Oncol; 2018 Jul; 150(1):143-150. PubMed ID: 29699801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.
    Yan XY; Zhang Y; Zhang JJ; Zhang LC; Liu YN; Wu Y; Xue YN; Lu SY; Su J; Sun LK
    Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins.
    Yu H; Su J; Xu Y; Kang J; Li H; Zhang L; Yi H; Xiang X; Liu F; Sun L
    Eur J Cancer; 2011 Jul; 47(10):1585-94. PubMed ID: 21371883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy.
    He J; Yu JJ; Xu Q; Wang L; Zheng JZ; Liu LZ; Jiang BH
    Autophagy; 2015; 11(2):373-84. PubMed ID: 25650716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system.
    Xia M; Yu H; Gu S; Xu Y; Su J; Li H; Kang J; Cui M
    Int J Oncol; 2014 Dec; 45(6):2341-8. PubMed ID: 25269472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL.
    Sun Q; Yogosawa S; Iizumi Y; Sakai T; Sowa Y
    Int J Oncol; 2015 Jan; 46(1):389-94. PubMed ID: 25310746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
    Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
    Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p62 aggregates mediated Caspase 8 activation is responsible for progression of ovarian cancer.
    Yan XY; Zhong XR; Yu SH; Zhang LC; Liu YN; Zhang Y; Sun LK; Su J
    J Cell Mol Med; 2019 Jun; 23(6):4030-4042. PubMed ID: 30941888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells.
    Mir R; Tortosa A; Martinez-Soler F; Vidal A; Condom E; Pérez-Perarnau A; Ruiz-Larroya T; Gil J; Giménez-Bonafé P
    Int J Cancer; 2013 Apr; 132(7):1525-36. PubMed ID: 22961628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
    Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T
    Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts.
    Washington MN; Suh G; Orozco AF; Sutton MN; Yang H; Wang Y; Mao W; Millward S; Ornelas A; Atkinson N; Liao W; Bast RC; Lu Z
    Cell Death Dis; 2015 Aug; 6(8):e1836. PubMed ID: 26247722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells.
    Babu A; Wang Q; Muralidharan R; Shanker M; Munshi A; Ramesh R
    Mol Pharm; 2014 Aug; 11(8):2720-33. PubMed ID: 24922589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing 50% inhibitory concentration (IC50) of cisplatin: a pilot study on the artifacts of the MTT assay and the precise measurement of density-dependent chemoresistance in ovarian cancer.
    He Y; Zhu Q; Chen M; Huang Q; Wang W; Li Q; Huang Y; Di W
    Oncotarget; 2016 Oct; 7(43):70803-70821. PubMed ID: 27683123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.